Psykologisk Institut

Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders. / Rømer Thomsen, Kristine; Thylstrup, Birgitte; Pedersen, Michael Mulbjerg; Pedersen, Mads Uffe; Simonsen, Erik; Hesse, Morten.

I: Schizophrenia Research, Bind 195, 2018, s. 495-500.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{01d10e04173445f6a310ef3442490e1f,
title = "Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders",
abstract = "BACKGROUND: Patients with schizophrenia and comorbid drug use disorders (DUD) have a severe course of illness. Despite strong evidence that drug use can exacerbate psychotic symptoms, we have limited knowledge of how specific drugs may increase risk of schizophrenia readmission in this group. This study aimed to assess drug-related predictors of readmission for schizophrenia among a national cohort of patients with a history of schizophrenia admitted to DUD treatment.METHODS: A record-linkage study was used to assess drug-related factors associated with readmission to mental health treatment for schizophrenia, using a consecutive cohort of 634 patients admitted to DUD treatment between 2000 and 2006 in Danish treatment services and tracked until February 2013 or death, controlling for baseline psychiatric treatment variables.RESULTS: The majority of patients were males (79.8{\%}) and the mean age was 34.7years. Of all patients, 78.7{\%} were readmitted for schizophrenia during follow-up, and 6.8{\%} died without having been readmitted. We found a robust association between use of amphetamine at baseline and elevated risk of readmission, a less robust association between use of cannabis and elevated risk of readmission, and no association with cocaine, opioids, alcohol, benzodiazepines, and MDMA. Furthermore, one or more psychiatric inpatients visit in the year prior to DUD admission was robustly associated with elevated risk of schizophrenia readmission.CONCLUSIONS: Use of amphetamine and cannabis are risk markers for schizophrenia readmission among patients with a history of schizophrenia and DUD. Psychiatric history is a predictor of schizophrenia readmission in this patient group.",
keywords = "Journal Article",
author = "{R{\o}mer Thomsen}, Kristine and Birgitte Thylstrup and Pedersen, {Michael Mulbjerg} and Pedersen, {Mads Uffe} and Erik Simonsen and Morten Hesse",
note = "Copyright {\circledC} 2017 Elsevier B.V. All rights reserved.",
year = "2018",
doi = "10.1016/j.schres.2017.09.026",
language = "English",
volume = "195",
pages = "495--500",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Drug-related predictors of readmission for schizophrenia among patients admitted to treatment for drug use disorders

AU - Rømer Thomsen, Kristine

AU - Thylstrup, Birgitte

AU - Pedersen, Michael Mulbjerg

AU - Pedersen, Mads Uffe

AU - Simonsen, Erik

AU - Hesse, Morten

N1 - Copyright © 2017 Elsevier B.V. All rights reserved.

PY - 2018

Y1 - 2018

N2 - BACKGROUND: Patients with schizophrenia and comorbid drug use disorders (DUD) have a severe course of illness. Despite strong evidence that drug use can exacerbate psychotic symptoms, we have limited knowledge of how specific drugs may increase risk of schizophrenia readmission in this group. This study aimed to assess drug-related predictors of readmission for schizophrenia among a national cohort of patients with a history of schizophrenia admitted to DUD treatment.METHODS: A record-linkage study was used to assess drug-related factors associated with readmission to mental health treatment for schizophrenia, using a consecutive cohort of 634 patients admitted to DUD treatment between 2000 and 2006 in Danish treatment services and tracked until February 2013 or death, controlling for baseline psychiatric treatment variables.RESULTS: The majority of patients were males (79.8%) and the mean age was 34.7years. Of all patients, 78.7% were readmitted for schizophrenia during follow-up, and 6.8% died without having been readmitted. We found a robust association between use of amphetamine at baseline and elevated risk of readmission, a less robust association between use of cannabis and elevated risk of readmission, and no association with cocaine, opioids, alcohol, benzodiazepines, and MDMA. Furthermore, one or more psychiatric inpatients visit in the year prior to DUD admission was robustly associated with elevated risk of schizophrenia readmission.CONCLUSIONS: Use of amphetamine and cannabis are risk markers for schizophrenia readmission among patients with a history of schizophrenia and DUD. Psychiatric history is a predictor of schizophrenia readmission in this patient group.

AB - BACKGROUND: Patients with schizophrenia and comorbid drug use disorders (DUD) have a severe course of illness. Despite strong evidence that drug use can exacerbate psychotic symptoms, we have limited knowledge of how specific drugs may increase risk of schizophrenia readmission in this group. This study aimed to assess drug-related predictors of readmission for schizophrenia among a national cohort of patients with a history of schizophrenia admitted to DUD treatment.METHODS: A record-linkage study was used to assess drug-related factors associated with readmission to mental health treatment for schizophrenia, using a consecutive cohort of 634 patients admitted to DUD treatment between 2000 and 2006 in Danish treatment services and tracked until February 2013 or death, controlling for baseline psychiatric treatment variables.RESULTS: The majority of patients were males (79.8%) and the mean age was 34.7years. Of all patients, 78.7% were readmitted for schizophrenia during follow-up, and 6.8% died without having been readmitted. We found a robust association between use of amphetamine at baseline and elevated risk of readmission, a less robust association between use of cannabis and elevated risk of readmission, and no association with cocaine, opioids, alcohol, benzodiazepines, and MDMA. Furthermore, one or more psychiatric inpatients visit in the year prior to DUD admission was robustly associated with elevated risk of schizophrenia readmission.CONCLUSIONS: Use of amphetamine and cannabis are risk markers for schizophrenia readmission among patients with a history of schizophrenia and DUD. Psychiatric history is a predictor of schizophrenia readmission in this patient group.

KW - Journal Article

U2 - 10.1016/j.schres.2017.09.026

DO - 10.1016/j.schres.2017.09.026

M3 - Journal article

C2 - 28965780

VL - 195

SP - 495

EP - 500

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -